Luis Ángel Fernández

This paper develops synthetic bacteria that target and inject proteins into tumor cells, reducing tumor growth in vivo.

This study demonstrates how ssDNA recombineering in bacteria enables hyper-diversification of nanobodies, resulting in variants that recognize new antigens while retaining original specificity.

The paper describes the development of a high-affinity Nanobody against SARS-CoV-2 RBD that neutralizes wild-type and D614G variants with nanomolar potency.

This paper develops a low-cost agglutination assay using E. coli-displayed nanobodies for detecting biomarkers with high selectivity and low detection limits, suitable for point-of-care testing.